Millennium Management
KRYS icon

Millennium Management’s Krystal Biotech KRYS Stock Holding History

Millennium Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,800
Closed -$752K – 6158
2024
Q4 		$752K Sell
4,800
-41,200
-90% -$7.31M ﹤0.01% 4426
2024
Q3 		$8.37M Buy
46,000
+42,400
+1,178% +$8.18M ﹤0.01% 2356
2024
Q2 		$661K Buy
+3,600
New +$604K ﹤0.01% 4418
2023
Q1 		– Sell
-7,700
Closed -$610K – 6613
2022
Q4 		$610K Buy
+7,700
New +$572K ﹤0.01% 4590
2021
Q2 		– Sell
-10,000
Closed -$770K – 6814
2021
Q1 		$770K Buy
+10,000
New +$727K ﹤0.01% 4456

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Millennium Management's KRYS Position: Q2 2026 in Review

Millennium Management sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 4,119 shares — an estimated $1.06M sold.

Millennium Management first reported a position in KRYS in Q4 2017 and held it in 22 quarters. The position peaked at $26.3M in Q3 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Millennium Management reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Millennium Management sold 4,119 Krystal Biotech shares in Q2 2026, an estimated $1.06M.
  • Millennium Management first reported a position in Krystal Biotech in Q4 2017 and held it in 22 quarters.
  • Millennium Management's Krystal Biotech position peaked at $26.3M in Q3 2025.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.